Does Aetna Cover Wegovy? Insurance Guide 2026

Weight loss and diabetes management have entered a new era with the introduction of GLP-1 receptor agonists like Wegovy. As a once-weekly injectable medication, Wegovy has demonstrated remarkable efficacy in clinical trials, offering hope to millions struggling with obesity and type 2 diabetes. However, the high cost of Wegovy—often exceeding $1,300 per month without insurance—makes coverage decisions by insurers like Aetna critically important for patients. This guide explores Aetna’s policies on Wegovy, including coverage criteria, cost-sharing details, and steps to take if your claim is denied.

Does Aetna Cover Wegovy for Diabetes?

Aetna’s coverage of Wegovy for diabetes management is contingent on specific clinical criteria. Wegovy, which contains the active ingredient semaglutide, is FDA-approved for chronic weight management but is also recognized for its benefits in improving glycemic control in patients with type 2 diabetes. Aetna typically covers Wegovy under its pharmacy benefit for diabetes if the patient meets certain conditions, such as a documented diagnosis of type 2 diabetes and prior failure to achieve glycemic targets with other antidiabetic medications (e.g., metformin, sulfonylureas, or SGLT2 inhibitors).

To qualify, patients must also demonstrate a body mass index (BMI) of 27 or higher with at least one weight-related comorbidity, such as hypertension or dyslipidemia. Aetna may require prior authorization to confirm that Wegovy is medically necessary and that the patient has exhausted other treatment options. Clinical evidence, such as HbA1c levels and weight history, is often required to support the request. If approved, Wegovy may be covered at a tiered copay, depending on the patient’s specific Aetna plan.

Does Aetna Cover Wegovy for Weight Loss?

Aetna provides coverage for Wegovy for chronic weight management, but only under strict criteria. Wegovy is FDA-approved for adults with a BMI of 30 or higher (obesity) or a BMI of 27 or higher (overweight) with at least one weight-related condition, such as hypertension, type 2 diabetes, or sleep apnea. Aetna’s policy aligns with these guidelines, requiring patients to meet these BMI thresholds and provide documentation of prior weight loss attempts through diet, exercise, or other lifestyle interventions.

Prior authorization is typically required for Wegovy coverage, and Aetna may limit approval to a specific duration (e.g., 12–24 weeks) before requiring proof of efficacy, such as a minimum of 5% weight loss. Patients must also be enrolled in a comprehensive weight management program, which may include nutritional counseling or behavioral therapy. Coverage for Wegovy is often subject to step therapy, meaning patients may need to try and fail other weight loss medications (e.g., phentermine or orlistat) before Wegovy is approved. Copays for Wegovy vary by plan but may range from $25 to $100 per month for preferred brand-name drugs.

How Much Does Wegovy Cost With Aetna?

The out-of-pocket cost of Wegovy with Aetna depends on the patient’s specific insurance plan, including whether the medication is classified as a preferred or non-preferred brand-name drug. Without insurance, Wegovy retails for approximately $1,300–$1,500 per month. With Aetna coverage, patients can expect to pay a tiered copay, which typically ranges from $25 to $100 per month for a 30-day supply if Wegovy is listed as a preferred medication. For non-preferred brands, the copay may be higher, sometimes reaching $150 or more per month.

Some Aetna plans may also require patients to meet a deductible before coverage kicks in, which can significantly increase the initial cost of Wegovy. For example, if a plan has a $1,000 deductible, the patient may need to pay the full cost of Wegovy until the deductible is met. Additionally, Aetna may limit the quantity of Wegovy covered per month, requiring patients to obtain prior authorization for refills. Patients are encouraged to review their plan’s formulary or contact Aetna directly to confirm their specific cost-sharing responsibilities for Wegovy.

Wegovy Prior Authorization for Aetna

Prior authorization is a standard requirement for Wegovy coverage under most Aetna plans. This process ensures that Wegovy is medically necessary and that the patient meets Aetna’s clinical criteria for coverage. To initiate prior authorization, the prescribing healthcare provider must submit a request to Aetna, including detailed documentation such as the patient’s BMI, weight history, and evidence of prior weight loss attempts (e.g., diet, exercise, or other medications). For patients with type 2 diabetes, additional documentation, such as HbA1c levels and a history of failed antidiabetic therapies, may be required.

Aetna reviews prior authorization requests within 3–14 days, depending on the urgency of the request. If approved, Wegovy coverage is typically authorized for a limited duration (e.g., 3–6 months), after which the provider may need to submit a renewal request with updated clinical evidence, such as documented weight loss or improved glycemic control. If the prior authorization is denied, the patient and provider will receive a denial letter outlining the reasons and instructions for appealing the decision.

How to Get Aetna to Cover Wegovy

Securing Aetna coverage for Wegovy requires a strategic approach, beginning with a thorough understanding of the insurer’s clinical criteria. Patients should first consult their healthcare provider to confirm that Wegovy is an appropriate treatment option and to gather the necessary documentation, such as BMI measurements, weight history, and evidence of prior weight loss attempts. For patients with type 2 diabetes, records of HbA1c levels and failed antidiabetic therapies are critical.

Next, the provider should submit a prior authorization request to Aetna, ensuring that all required documentation is included. Patients can also proactively contact Aetna to confirm their plan’s specific coverage criteria for Wegovy and to inquire about any additional requirements, such as enrollment in a weight management program. If the prior authorization is denied, patients should work with their provider to appeal the decision by submitting additional clinical evidence or a letter of medical necessity. Persistence and thorough documentation are key to successfully obtaining Aetna coverage for Wegovy.

What to Do If Aetna Denies Wegovy

If Aetna denies coverage for Wegovy, patients have several options to challenge the decision. The first step is to review the denial letter carefully, as it will outline the specific reasons for the denial and provide instructions for appealing the decision. Common reasons for denial include failure to meet BMI criteria, lack of documentation for prior weight loss attempts, or incomplete prior authorization requests.

Patients should work with their healthcare provider to gather additional evidence, such as updated BMI measurements, records of failed weight loss interventions, or a letter of medical necessity explaining why Wegovy is the most appropriate treatment option. The provider can then submit an appeal to Aetna, which may involve a peer-to-peer review with an Aetna medical director. If the appeal is denied, patients can escalate the matter to an external review board or explore alternative funding options, such as manufacturer coupons or patient assistance programs. Legal advocacy groups may also provide support for patients navigating insurance denials.

Aetna Alternatives If Wegovy Is Not Covered

If Aetna denies coverage for Wegovy, patients may explore alternative medications or financial assistance programs. Other GLP-1 receptor agonists, such as Saxenda (liraglutide) or Zepbound (tirzepatide), may be covered under Aetna’s formulary and could serve as viable alternatives. Patients should consult their healthcare provider to determine if these medications are clinically appropriate and to initiate a prior authorization request if necessary.

For patients facing high out-of-pocket costs, Novo Nordisk, the manufacturer of Wegovy, offers a savings card that can reduce the monthly cost to as low as $0 for eligible patients with commercial insurance. Additionally, patients without insurance or with limited coverage may qualify for Novo Nordisk’s patient assistance program, which provides Wegovy at no cost to qualifying individuals. Other weight loss medications, such as phentermine or orlistat, may also be covered by Aetna and could be considered as interim solutions while pursuing coverage for Wegovy.

Frequently Asked Questions

Does Aetna cover Wegovy for weight loss?

Aetna covers Wegovy for weight loss if the patient meets specific clinical criteria, including a BMI of 30 or higher (or 27 or higher with a weight-related comorbidity) and documented prior weight loss attempts. Prior authorization is typically required, and coverage may be limited to patients enrolled in a comprehensive weight management program.

How much is the Wegovy copay with Aetna?

The copay for Wegovy with Aetna varies by plan but typically ranges from $25 to $100 per month for preferred brand-name drugs. Patients with high-deductible plans may need to pay the full cost of Wegovy until their deductible is met. It is advisable to review your plan’s formulary or contact Aetna for specific cost-sharing details.

Can I appeal if Aetna denies Wegovy?

Yes, patients can appeal an Aetna denial for Wegovy by working with their healthcare provider to submit additional clinical evidence or a letter of medical necessity. The appeal process may involve a peer-to-peer review with an Aetna medical director, and patients can escalate the matter to an external review board if the appeal is denied.

Disclaimer from HealthLeague Medical Board: The information provided in this article is for educational purposes only and does not constitute medical or insurance advice. Coverage policies for Wegovy may vary by plan and are subject to change. Patients should consult their healthcare provider and Aetna directly to confirm coverage details and clinical eligibility for Wegovy.